Quest Diagnostics Incorporated $DGX Shares Sold by Keybank National Association OH

Key Points

• KeyBank National Association OH cut its stake in Quest Diagnostics (NYSE:DGX) by 47.3% in Q4, selling 6,745 shares and leaving 7,505 shares valued at $1.302 million.
• Quest Diagnostics beat Q1 expectations with $2.50 EPS versus a $2.37 estimate and $2.90 billion in revenue versus $2.83 billion, and set FY2026 guidance of $10.630–$10.830 EPS (analysts' average ~10.71).
• The company increased its quarterly dividend to $0.86 (annualized $3.44, ~1.8% yield) and authorized a $1.0 billion share buyback (about 4.7% of shares), signaling management confidence in the stock.

Keybank National Association OH decreased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 47.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,505 shares of the medical research company's stock after selling 6,745 shares during the period. Keybank National Association OH's holdings in Quest Diagnostics were worth $1,302,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of DGX. Brighton Jones LLC acquired a new position in Quest Diagnostics during the 4th quarter valued at about $323,000. Cresset Asset Management LLC increased its stake in Quest Diagnostics by 4.6% during the 2nd quarter. Cresset Asset Management LLC now owns 4,003 shares of the medical research company's stock valued at $719,000 after buying an additional 176 shares during the period. Gabelli Funds LLC acquired a new position in Quest Diagnostics during the 2nd quarter valued at about $287,000. Bank of Nova Scotia increased its stake in Quest Diagnostics by 7.2% during the 2nd quarter. Bank of Nova Scotia now owns 14,339 shares of the medical research company's stock valued at $2,576,000 after buying an additional 962 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in Quest Diagnostics by 17.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 18,599 shares of the medical research company's stock valued at $3,341,000 after buying an additional 2,718 shares during the period. Institutional investors and hedge funds own 88.06% of the company's stock.

Quest Diagnostics Stock Performance

Shares of DGX opened at $192.50 on Friday. Quest Diagnostics Incorporated has a one year low of $164.65 and a one year high of $213.50. The company has a 50-day moving average of $199.17 and a two-hundred day moving average of $189.69. The stock has a market cap of $21.31 billion, a price-to-earnings ratio of 21.27, a PEG ratio of 2.30 and a beta of 0.60. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion during the quarter, compared to analysts' expectations of $2.83 billion. During the same period last year, the company posted $1.94 earnings per share. The business's revenue for the quarter was up 9.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, equities research analysts expect that Quest Diagnostics Incorporated will post 10.71 earnings per share for the current year.

Quest Diagnostics Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 20th. Investors of record on Monday, April 6th were issued a dividend of $0.86 per share. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.80. This represents a $3.44 annualized dividend and a dividend yield of 1.8%. The ex-dividend date was Monday, April 6th. Quest Diagnostics's dividend payout ratio is 38.01%.

Quest Diagnostics announced that its board has approved a stock repurchase program on Tuesday, February 10th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 4.7% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its stock is undervalued.

Analyst Ratings Changes

DGX has been the topic of several research analyst reports. Mizuho raised their target price on shares of Quest Diagnostics from $210.00 to $235.00 and gave the company an "outperform" rating in a research note on Thursday, February 12th. Citigroup raised their target price on shares of Quest Diagnostics from $190.00 to $215.00 and gave the company a "neutral" rating in a research note on Tuesday, February 10th. Truist Financial raised their target price on shares of Quest Diagnostics from $220.00 to $225.00 and gave the company a "hold" rating in a research note on Wednesday, April 22nd. Wall Street Zen upgraded shares of Quest Diagnostics from a "hold" rating to a "buy" rating in a research report on Saturday, April 25th. Finally, Barclays raised their price objective on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, Quest Diagnostics presently has a consensus rating of "Hold" and a consensus target price of $214.54.

Insider Activity at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 3,878 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $799,682.38. Following the completion of the sale, the senior vice president directly owned 37,557 shares in the company, valued at approximately $7,744,628.97. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Karthik Kuppusamy sold 2,628 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $204.86, for a total transaction of $538,372.08. Following the sale, the senior vice president owned 13,441 shares of the company's stock, valued at approximately $2,753,523.26. This represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 24,083 shares of company stock valued at $4,945,262. 0.88% of the stock is owned by company insiders.

Quest Diagnostics Company Profile

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.